SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-001679
Filing Date
2023-03-22
Accepted
2023-03-22 17:05:08
Documents
14
Period of Report
2023-03-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 27444
2 PRESS RELEASE phio_ex9901.htm EX-99.1 44173
6 GRAPHIC image_001.jpg GRAPHIC 2326
  Complete submission text file 0001683168-23-001679.txt   257138

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20230322.xsd EX-101.SCH 3233
4 XBRL LABEL FILE phio-20230322_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE phio-20230322_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3614
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 23753631
SIC: 2834 Pharmaceutical Preparations